Inspire Medical Systems, Inc. INSP
We take great care to ensure that the data presented and summarized in this overview for Inspire Medical Systems, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INSP
View all-
Vanguard Group Inc Valley Forge, PA3.27MShares$580 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.86MShares$329 Million0.01% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.32MShares$234 Million1.23% of portfolio
-
Baillie Gifford & CO1.26MShares$223 Million0.18% of portfolio
-
State Street Corp Boston, MA1.06MShares$188 Million0.01% of portfolio
-
William Blair Investment Management, LLC Chicago, IL903KShares$160 Million0.44% of portfolio
-
Dragoneer Investment Group, LLC San Francisco, CA871KShares$154 Million3.53% of portfolio
-
Invesco Ltd. Atlanta, GA793KShares$141 Million0.03% of portfolio
-
Morgan Stanley New York, NY585KShares$104 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X0567KShares$101 Million0.06% of portfolio
Latest Institutional Activity in INSP
Top Purchases
Top Sells
About INSP
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Insider Transactions at INSP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 13
2025
|
Bryan K Phillips Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,076
+35.33%
|
-
|
|
Feb 13
2025
|
Richard Buchholz Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,076
+13.45%
|
-
|
|
Feb 13
2025
|
Carlton Weatherby Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,076
+40.5%
|
-
|
|
Feb 13
2025
|
Timothy P. Herbert CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
16,029
+39.1%
|
-
|
|
Feb 13
2025
|
John Rondoni Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,076
+24.67%
|
-
|
|
Feb 13
2025
|
Melissa Mann Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,076
+38.05%
|
-
|
|
Feb 13
2025
|
Randy Ban Officer |
SELL
Open market or private sale
|
Direct |
25,584
-13.59%
|
$4,681,872
$183.26 P/Share
|
|
Feb 13
2025
|
Randy Ban Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+43.22%
|
$1,675,000
$67.63 P/Share
|
|
Feb 13
2025
|
Randy Ban Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,076
+39.29%
|
-
|
|
Feb 11
2025
|
John Rondoni Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
583
-5.3%
|
$99,110
$170.49 P/Share
|
|
Feb 09
2025
|
Bryan K Phillips Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
282
-6.27%
|
$51,324
$182.15 P/Share
|
|
Feb 09
2025
|
Richard Buchholz Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
314
-1.13%
|
$57,148
$182.15 P/Share
|
|
Feb 09
2025
|
Carlton Weatherby Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
313
-11.62%
|
$56,966
$182.15 P/Share
|
|
Feb 09
2025
|
Timothy P. Herbert CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
896
-9.11%
|
$163,072
$182.15 P/Share
|
|
Feb 09
2025
|
Randy Ban Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
314
-10.19%
|
$57,148
$182.15 P/Share
|
|
Feb 09
2025
|
John Rondoni Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
315
-2.78%
|
$57,330
$182.15 P/Share
|
|
Jan 29
2025
|
Bryan K Phillips Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
204
-4.34%
|
$38,556
$189.99 P/Share
|
|
Jan 15
2025
|
Gary Lee Ellis Director |
BUY
Grant, award, or other acquisition
|
Direct |
137
+3.0%
|
$24,112
$176.33 P/Share
|
|
Jan 15
2025
|
Casey M Tansey Director |
BUY
Grant, award, or other acquisition
|
Direct |
81
+0.39%
|
$14,256
$176.33 P/Share
|
|
Jan 15
2025
|
Georgia Melenikiotou Director |
BUY
Grant, award, or other acquisition
|
Direct |
80
+3.37%
|
$14,080
$176.33 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 56.9K shares |
|---|---|
| Exercise of conversion of derivative security | 88.3K shares |
| Bona fide gift | 500 shares |
| Bona fide gift | 3.56K shares |
|---|---|
| Payment of exercise price or tax liability | 2.64K shares |
| Open market or private sale | 135K shares |
| Other acquisition or disposition | 61.8K shares |